High-Resolution Computed Tomography and Pulmonary Function Findings of Occupational Arsenic Exposure in Workers

Yıl 2017, Cilt: 34 Sayı: 3, 263 - 268, 01.05.2017

Recai Ergün Ender Evcik Dilek Ergün Begüm Ergan Esin Özkan Özge Gündüz

Öz

Background: The number of studies where non-malignant pulmonary diseases are evaluated after occupational arsenic exposure is very few. Aims: To investigate the effects of occupational arsenic exposure on the lung by high-resolution computed tomography and pulmonary function tests. Study Design: Retrospective cross-sectional study. Methods: In this study, 256 workers with suspected respiratory occupational arsenic exposure were included, with an average age of 32.9±7.8 years and an average of 3.5±2.7 working years. Hair and urinary arsenic levels were analysed. High-resolution computed tomography and pulmonary function tests were done. Results: In workers with occupational arsenic exposure, high-resolution computed tomography showed 18.8% pulmonary involvement. In pulmonary involvement, pulmonary nodule was the most frequently seen lesion (64.5%). The other findings of pulmonary involvement were 18.8% diffuse interstitial lung disease, 12.5% bronchiectasis, and 27.1% bullae-emphysema. The mean age of patients with pulmonary involvement was higher and as they smoked more. The pulmonary involvement was 5.2 times higher in patients with skin lesions because of arsenic. Diffusing capacity of lung for carbon monoxide was significantly lower in patients with pulmonary involvement. Conclusion: Besides lung cancer, chronic occupational inhalation of arsenic exposure may cause non-malignant pulmonary findings such as bronchiectasis, pulmonary nodules and diffuse interstitial lung disease. So, in order to detect pulmonary involvement in the early stages, workers who experience occupational arsenic exposure should be followed by diffusion test and high-resolution computed tomography.

Anahtar Kelimeler

Arsenic, occupational disease, pulmonary function

Kaynakça

• 1. Kapaj S, Peterson H, Liber K, Bhattacharya P. Human health effects from chronic arsenic poisoning-a review. J Environ Sci Health A Tox Hazard Subst Environ Eng 2006;41:2399-428.
• 2. Lubin JH, Moore LE, Fraumeni JF Jr, Cantor KP. Respiratory cancer and inhaled inorganic arsenic in copper smelters workers: a linear relationship with cumulative exposure that increases with concentration. Environ Health Perspect 2008;116:1661-5.
• 3. De BK, Majumdar D, Sen S, Guru S, Kundu S. Pulmonary involvement in chronic arsenic poisoning from drinking contaminated ground-water. J Assoc Physicians India 2004;52:395-400.
• 4. Bhattacharyya P, Sen P, Ghosh A, Saha C, Bhattacharya PP, Das A, et al. Chronic lung disease and detection of pulmonary artery dilatation in high resolution computerized tomography of chest in chronic arsenic exposure. J Environ Sci Health A Tox Hazard Subst Environ Eng 2014;49:1453-61.
• 5. Mazumder DN, Steinmaus C, Bhattacharya P, von Ehrenstein OS, Ghosh N, Gotway M, et al. Bronchiectasis in persons with skin lesions resulting from arsenic in drinking water. Epidemiology 2005;16:760-5.
• 6. Chen CJ, Chuang YC, Lin TM, Wu HY. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 1985;45:5895-9.
• 7. Zaldívar R, Ghai GL. Clinical epidemiological studies on endemic chronic arsenic poisoning in children and adults, including observations on children with high- and low-intake of dietary arsenic. Zentralbl Bakteriol B 1980;170:409-21.
• 8. Rosenberg HG. Systemic arterial disease and chronic arsenicism in infants. Arch Pathol 1974;97:360-5.
• 9. Lynch DA, Newell J, Hale V, Dyer D, Corkery K, Fox NL, et al. Correlation of CT findings with clinical evaluations in 261 patients with symptomatic bronchiectasis. AJR Am J Roentgenol 1999;173:53-8.
• 10. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
• 11. Mazumder DN, Gupta JD, Santra A, Pal A, Ghose A, Sarkar S, et al. Noncancer effects of chronic arsenicosis with special reference to liver damage. Springer 1997;112-23.
• 12. Mazumder DN, Haque R, Ghosh N, De BK, Santra A, Chakraborti D, et al. Arsenic in drinking water and the prevalence of respiratory effects in West Bengal, India. Int J Epidemiol 2000;29:1047-52.
• 13. Gerhardsson L, Brune D, Nordberg GF, Wester PO Multielemental assay of tissues of deceased smelter workers and controls. Sci Total Environ 1988;74:97-110.
• 14. King TE, S.M., Approach to diagnosis and management of the idiopathic interstitial pneumonias. Pulmonary function testing., in Murray&Nadel’s Textbook of Respiratory Medicine, J.A.N. John F. Murray, Editor. 2005, Elsevier Saunders: Philadelphia. p. 1671-90.
• 15. Chetta A, Marangio E, Olivieri D. Pulmonary function testing in interstitial lung diseases. Respiration 2004;71:209-13.
• 16. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Some drinking-water disinfectants and contaminants, including arsenic. IARC Monogr Eval Carcinog Risks Hum 2004;84:1-447.
• 17. Hotta N. Clinical aspects of chronic arsenic poisoning due to environmental and occupational pollution in and around a small refining spot. Japanese J Constitutional Med 1989;53:49-70.
• 18. Hunnibell LS, Slatore CG, Ballard EA. Foundations for lung nodule management for nurse navigators. Clin J Oncol Nurs 2013;17:525-31.